Journal article icon

Journal article

Randomised trial of delivering co-located, personalised stop-smoking support within lung cancer screening: the YESS study

Abstract:
Introduction Lung cancer screening (LCS) with low-dose CT offers a teachable moment for smoking cessation (SC), but the optimal way to implement SC within LCS is unclear. The Yorkshire Enhanced Stop Smoking (YESS) study assessed the efficacy of a personalised stop-smoking intervention delivered alongside LCS.Methods Opt-out, co-located SC support, comprising nicotine replacement therapy/e-cigarettes/pharmacotherapy and behavioural support, was offered to all individuals who currently smoked attending for LCS. Four weeks later, participants were offered recruitment to a randomised controlled trial of continued standard best practice (SBP) versus a personalised SC support package, including a booklet containing CT images of participants’ own heart and lungs, annotated where appropriate to highlight emphysema or coronary artery calcification and scripted communication delivered by a smoking cessation practitioner.Results 1003 people were recruited; 52.5% were allocated to the intervention group. Validated 7-day point prevalent (PP) abstinence rates were 33.6% and 30.0% in the intervention versus SBP groups, respectively (OR 1.17, 95% CI 0.90 to 1.54) at 3 months and 29.2% versus 28.6% (OR 1.03, 95% CI 0.78 to 1.36) at 12 months post-screening. Subgroup analyses indicated a significant increase in 7-day PP abstinence at 3 months with the intervention in women (33.9% intervention, 23.1% SBP, OR 1.70, 95% CI 1.15 to 2.53) but not in men (33.3% intervention, 37.8% SBP, OR 0.82, 95% CI 0.57 to 1.19).Conclusion Around one-third of study participants were abstinent from smoking at 3 months post-screening irrespective of study arm, but adding the personalised intervention did not increase quit rates. Further research is needed exploring possible sex differences in efficacy of personalised SC support. The high overall quit rate reinforces the value of SC support delivered alongside LCS.Trial registration number ISRCRN 63825779 and NCT03750110
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Authors

More by this author
Role:
Author
ORCID:
0000-0001-5477-2557
More by this author
Role:
Author
ORCID:
0000-0001-8410-7160
More by this author
Role:
Author
ORCID:
0000-0001-9296-9748
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0836-9385


Publisher:
BMJ Publishing Group
Journal:
Thorax More from this journal
Pages:
thorax-2025
Publication date:
2026-03-13
DOI:
EISSN:
1468-3296
ISSN:
0040-6376


Language:
English
Keywords:
Pubs id:
2406111
Local pid:
pubs:2406111
Source identifiers:
W7135190796
Deposit date:
2026-04-23
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP